From Mumbai to the Frontier of Genetic Medicine: How Reshma Kewalramani is Scaling Vertex Pharmaceuticals Globally
What is the news?
Reshma Kewalramani’s tenure as CEO of Vertex Pharmaceuticals represents a pivotal moment for Indian-origin leadership in the global deep-tech and life sciences sectors. Since taking the helm in 2020, Kewalramani has moved the company beyond its established dominance in cystic fibrosis into the “frontier” of medicine. Her leadership was instrumental in the recent global rollout of CRISPR-based therapies, marking a historic shift in how chronic genetic conditions are treated worldwide.
Why is it interesting?
Born in Mumbai and educated in the United States, Kewalramani embodies the “Global-First” strategic approach. Under her guidance, Vertex has not only expanded its clinical pipeline into pain management and type 1 diabetes but has also solidified its role as a global innovation hub. By successfully navigating the complexities of international regulatory environments and cutting-edge R&D, she has demonstrated how Indian-origin leaders are providing the intellectual capital necessary to solve some of the world’s most difficult health challenges.
Read more: Reshma Kewalramani: Indian-Origin CEO Leading Vertex Pharmaceuticals and Biotech Innovation